Clinical Trials Interview June 2022, page-2

The thing I picked up on is the conundrum of whether to get FDA registration on our own, which i believe would allow Pharmaust to get a bigger price, or to allow a partner to take on the risk of obtaining registration at a lower price. That would obviously put some money in the coffers sooner. RA appeared to acknowledge he believes share holders would prefer the later.

I need to watch it again as he appeared to say talks on the Canine treatment are now more advanced and focused. But its very difficult for a CEO to give much away until there is at lest an agreement to negotiate a price. Just a "we are very interested" is not enough to make an announcement, we need a yes "we will negotiate a price".

Not sure what others think but I'm for selling the canine license at a reduced price if it fills the coffers and expedites the other applications. But we are all in different situations. I would be particularly like to know what the top 10 or 20 holders think. I'm a little out of the 20 so no real influence.


Pete